- Home
- AGEN vs ORGN Comparison
AGEN vs ORGN Comparison
Compare AGEN & ORGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGEN | ORGN |
|---|---|---|
| Founded | 1994 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 109.4M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | AGEN | ORGN |
|---|---|---|
| Price | $3.23 | $0.20 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | 901.2K | ★ 2.2M |
| Earning Date | 03-10-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $106,829,000.00 | $25,122,000.00 |
| Revenue This Year | $23.68 | $49.18 |
| Revenue Next Year | $23.17 | $144.81 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.38 | $0.18 |
| 52 Week High | $7.34 | $1.12 |
Technical Indicators
Market Signals| Indicator | AGEN | ORGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.39 | 35.59 |
| Support Level | $3.12 | $0.18 |
| Resistance Level | $3.55 | $0.23 |
| Average True Range (ATR) | 0.38 | 0.02 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 6.57 | 29.29 |
Price Performance
Historical ComparisonAbout AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About ORGN Origin Materials Inc.
Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others by using materials like food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, and fuels.